NCT02801370

Brief Summary

This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study in which eligible subjects with acute otitis externa (AOE) will be randomized to receive a single administration of either 12 mg OTO-201 or Sham-Control (empty syringe) to the external auditory canal of the affected ear(s).

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
262

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jun 2016

Shorter than P25 for phase_3

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

June 13, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 15, 2016

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
3.8 years until next milestone

Results Posted

Study results publicly available

September 22, 2020

Completed
Last Updated

October 19, 2020

Status Verified

September 1, 2020

Enrollment Period

5 months

First QC Date

June 13, 2016

Results QC Date

September 1, 2020

Last Update Submit

September 21, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Subjects Considered a Clinical Cure at Day 8

    Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows: None = 0 Mild = 1 Moderate = 2 Severe = 3

    At Day 8 (1 week after dosing)

Secondary Outcomes (1)

  • Number of Subjects Considered a Clinical Cure at Day 15

    At Day 15 (2 weeks after dosing)

Study Arms (2)

OTO-201

EXPERIMENTAL
Drug: 12 mg ciprofloxacin

Control

SHAM COMPARATOR
Drug: Sham Control

Interventions

Single administration of OTO-201

Also known as: OTIPRIO
OTO-201

Simulated, single adminstration

Control

Eligibility Criteria

Age6 Months+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is a male or female age 6 months or older
  • Subject has a clinical diagnosis of unilateral or bilateral acute otitis externa
  • Subject or subject's caregiver is willing to comply with the protocol and attend all study visits

You may not qualify if:

  • Subject has tympanic membrane perforation
  • Subject has eczematoid otitis externa
  • Subject has diabetes mellitus

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Call Otonomy call center for trial locations

San Diego, California, 92121, United States

Location

Call Otonomy call center for trial locations

Saskatoon, Canada

Location

MeSH Terms

Conditions

Otitis Externa

Interventions

Ciprofloxacin

Condition Hierarchy (Ancestors)

OtitisEar DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Fluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title
Medical Information Call Center
Organization
Otonomy

Study Officials

  • Carl LeBel, PhD

    Otonomy, Inc.

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2016

First Posted

June 15, 2016

Study Start

June 1, 2016

Primary Completion

November 1, 2016

Study Completion

December 1, 2016

Last Updated

October 19, 2020

Results First Posted

September 22, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations